Table 6 Factors influencing the seroprevalence of anti-CSP antibodies

Age group (year)

 <1

62 (42.47%)

1

1

 1–4

378 (37.8%)

0.82 (0.57–1.17)

0.85 (0.59–1.21)

0.38

 5–10

313 (43.53%)

1.04 (0.73–1.5)

1.08 (0.75–1.56)

0.66

Gender

 Female

376 (41%)

1

1

 Male

377 (39.77%)

0.95 (0.78–1.14)

0.98 (0.81–1.19)

0.86

Nutritional status

 Stunting

289 (43.72%)

1.24 (1.02–1.5)

1.09 (0.85–1.4)

0.45

 Underweight

191 (38.43%)

0.89 (0.72–1.1)

0.88 (0.64–1.09)

0.19

 Wasting

55 (28.06%)

0.54 (0.4 0.75)

0.61 (0.43–0.86)

0.005

Anemia

 No

207 (40.19%)

1

1

 Yes

546 (40.44%)

1.01 (0.82–1.24)

0.87 (0.69–1.1)

0.25

Malaria parasite

 No

710 (40.07%)

1

1

 Yes

43 (46.24%)

1.28 (0.085–1.95)

1.2 (0.78–1.84)

0.4

Residence area

 Keur Soce

297 (29.73%)

1

1

 Velingara

456 (52.66%)

2.63 (2.17–3.17)

2.63 (2.13–3.24)

<10⁻³